Clinical Stage Precision Immunology Company

Startup building population-scale biobank that is disease-agnostic

As the Interim Chief Business Officer (starting in Nov. 2022), my role involves developing the company's partnership strategy by focusing on AI target discovery collaborations, biomarker & CDx deals, and other applications using Scipher's novel AI network biology SPECTRA platform, including scoping and evaluating in-licensing clinical-stage therapeutic assets. I leverage my relationships in the life sciences ecosystem and help structure innovative deals, efficiently and with speed.

As General Counsel, corporate secretary and member of the executive team of a venture-backed precision medicine biotech company focused on autoimmune and inflammatory disease, I lead patent and IP strategy, litigation, compliance, governance, advising the board and CEO, securities, all transactional matters, including an oversubscribed $120 million crossover round in 2022 (with Northpond, Khosla Ventures, Cowen, Neuberger Berman, aMoon, among others), an acquisition of a SAAS company in October 2022, multiple licenses and collaborations with biopharma, and payer strategy. My legal expertise and leadership play a significant role in shaping the company's growth and success. Ask me about Legal 2.0.

Strategic Advisor, BD, GSD

First legal hire for NASDAQ-listed, EQRx, in a leadership capacity, I reported directly to the CEO, and led all transactional matters, including a $500+ million Series B crossover round, a $5.35 billion business combination with CM Life Sciences III, including its $1.2 billion PIPE financing, 10 license and collaborations, all agreements with payers/payors and health systems, all clinical and commercial agreements, managing the legal budget, led patent strategy, assisted with HR matters, and founded of Modern Vision Legal.

Corporate, M&A, Private Equity, Emerging Companies and Venture Capital | Life Sciences | License & Collaboration | China Transactions | Founder of McDermott Rise https://mcdermottrise.mwe.comhttps://www.mwe.com/alumni/spotlight/sam-davis/Representative clients: Ampersand Capital, Merck KGaA, Simcere Pharma, Scipher Medicine, Anthro Ventures.

Corporate | Life SciencesRepresentative clients: Thrive Earlier Detection, FMI (Foundation Medicine), Teva, Scholar Rock, Ikena Oncology, and both the funds and the portfolio companies of Atlas Venture, Deerfield Management, Third Rock Ventures, SV Life Sciences, DDF, and others.

Corporate | Life Sciences & Technology Transactions

https://www.clinicalbox.com

Cross-border M&A, JVs, and commercial transactions

Cross-border M&A, VC & PE

Under SJC Rule 3:03, represented pro-bono clients in Federal administrative appeals for disability benefits.